Sign up for otohns.net!  2/9/2010
News This weeks' news Media Page   Clinical Resources Facial Plastics & Reconstructive Surgery Head & Neck Oncology Laryngology Otology / Neurotology Pediatric Otolaryngology Practice Management Rhinology Snoring & Sleep Apnea   Forums otohns pedi-oto   Library Medline Knowledge Finder otohns Bookstore UTMB Grand Rounds Endoscopic Sinus Surgery Congress Reporter   Image Library Disorders of The Larynx Facial Fractures Floor of Mouth Line Art   Conferences Conference Calendar Conference Reporter   Patient Education   Resources and Links otohns Job Search otohns Vendor Database Build a Web Page   otohns Directories Associations and Organizations   Financial Links   Britannica.com   DailyStocks.com   EquityWeb   Hoover's   InvestorNet   JustQuotes.com   JustQuoteMe.com   MSN MoneyCentral   TradingDay.com   Wall Street Research Net   Yahoo! Finance   Advisory Boards All Board Members   About Us Our Staff About Otohns.net About MediSpecialty.com How to Get Involved Become a Sponsor Terms and Conditions Privacy Statement   Help! Acronym Expander   Contact Us   Home We subscribe to the HONcode principles of the Health On the Net Foundation	John J. Murray, MD, PhD International Advisory Board Curriculum Vitae Send Dr. Murray e-mail Articles and Interviews on OTOHNS.net "Is There a 'Yeast Connection' for Sinusitis"  "Leukotriene Modifier Therapy of Rhinitis and Nasal Polyps"  "Stepped-Care Approach To The Medical Management of Asthma" Personal Data  Birth date and Place: April 19, 1951 - Boston, Massachusetts  Married with two children Office Address:  Vanderbilt ASAP - Asthma, Sinus, Allergy Program 2611 West End Avenue Suite 120 Nashville, Tennessee 37203 (615) 936-5764 (615) 936-5828 (facsimile) Education Secondary:  Boston Latin  Boston, Massachusetts  (1963-1969)  Undergraduate:  Harvard College  Cambridge, Massachusetts  Major: Applied Mathematics  1969-1973 A.B. degree with honors, 1973  Graduate:  University of Massachusetts School of Medicine  Worcester, Massachusetts  Doctor of Medicine Program  1973-1975  Vanderbilt University School of Medicine  Nashville, Tennessee  Doctor of Philosophy Program in Pharmacology NIH Doctoral Fellow and Vivian Allen Scholar Advisors - Drs. Joel Hardman and Peter Reed Doctor of Medicine Program  1975-1979 M.D., Ph.D. degrees, 1979 Myasnikov Institute of Cardiology Moscow, Russia U.S.S.R.  Exchange Fellow of the National Heart, Lung and Blood Institute and the Soviet Academy of Sciences  1977 Postgraduate:  Vanderbilt University School of Medicine  Nashville, Tennessee  Internship in Internal Medicine - 1979-1980  Residency in Internal Medicine  - 1980-1982  Hugh J. Morgan Chief Resident in Medicine - Chairman, Dr. Grant W. Liddle - 1982-1983  Research Fellow in Clinical Pharmacology - Advisor - Dr. John A. Oates  NIH Postdoctoral Fellow - 1983-1984  Pfizer Postdoctoral Fellow - 1984-1985  Duke University School of Medicine - Howard Hughes Medical Institute Durham, North Carolina  Fellow in Rheumatology/Immunology - Advisor - Dr. Ralph Snyderman  Fellow in Allergy/Immunology/Pulmonary - Advisors - Drs. C.E. Buckley, III and James Crapo Pfizer Postdoctoral Fellow - 1985-1986  Professional Appointments Vanderbilt University School of Medicine  Nashville, TN  Instructor in Medicine  Division of Clinical Pharmacology 1985  Duke University School of Medicine  Durham, NC Assistant Professor of Medicine Division of Allergy, Critical Care and Respiratory Medicine  Division of Rheumatology and Immunology Attending Physician, Duke University Hospital 1986 - 1988  Vanderbilt University Medical Center Nashville, TN Assistant Professor of Medicine  Assistant Professor of Pharmacology Division of Allergy and Immunology Division of Clinical Pharmacology 1988 - 1994 Vanderbilt University School of Medicine  Nashville, TN  Attending Physician, Vanderbilt University Hospital 1988-present Investigator - Center for Lung Research  1993 - present Associate Professor of Medicine  Associate Professor of Pharmacology Division of Allergy and Immunology  Division of Clinical Pharmacology 1994 - 1995 Associate Professor of Medicine  Associate Professor of Pharmacology Division of Allergy, Pulmonary, and Critical Care Medicine Division of Clinical Pharmacology 1995 - present The Elizabeth and John Murray Professor of Medicine (Fully endowed chair at the medical center - funded from research grants from pharmaceutical companies) 1998 - present Vanderbilt ASAP - Asthma, Sinus, Allergy Program Chief Operating Officer Director of Clinical Research 1997 - Date Veterans Administration Hospital Nashville, TN Attending Physician  1988 - Date Centennial Medical Center (HCA System) Nashville, TN Staff Physician 1995- Date Awards Vivian Allen Scholar, 1977-1979  Exchange Fellow NIH-NHLBI and Soviet Academy of Sciences, 1977 Hospital Award of Excellence, 1979  Louis Weinstein Award in Medicine, 1979  Pfizer Research Fellowship, 1984-1987  RJ Reynolds Research Award, 1986-1987  RJR Nabisco Scholar Award, 1987-1990  First edition of "Best Doctors in America: Midwest Region", 1995. First edition of "Who's Who in Medicine and Healthcare", 1997-1998. Second edition of "Who's Who in Medicine and Healthcare", 1998-1999. Fifteenth edition of "Who's Who in the World", 1997 Who’s Who in International Business, 1998 2000 Outstanding People for the 20th Century Who’s Who of International Professionals, 1998 Best Doctors in America 1998-present Certifications National Board of Medical Examiners, certified 1980  American Board of Internal Medicine, certified 1983, 99th percentile  American Board of Allergy and Immunology, certified 1987  American Board of Rheumatology and Immunology, eligible 1987 American Board of Pulmonary Medicine, eligible 1987 American Board of Clinical Pharmacology, eligible 1990 Certified by the Office of Biologics of the FDA for standardization of allergic extracts CLIA laboratory certification, 1994- present Memberships and Licenses American College of Physicians, Member  American Federation for Clinical Research, Member  Southeast Allergy Association, Member American Academy of Allergy and Immunology, Member Tennessee State Allergy Association, Member North Carolina Medical License Tennessee Medical License Consultant American Board of Internal Medicine, Recertification examination questioner, 1992.  Abbott Asthma Advisory Board  Marion-Merrell Dow, Zeneca, Rhone Poulenc Rorer, Merck, Bayer, Smith Kline Beecham, Schering- Plough, Aventis, Novartis - Consultant and national speaker  Searle Asthma Advisory Board Wallace Laboratory National Allergy Advisory Council Hoechst-Roussell advisory panel for allergic diseases Breathe America, Inc. GlaxoWellcome Speaker for National Speaker Training courses and Consumer Advisory Panels Pfizer, GlaxoWellcome, and Merck - Moderator/speaker for national teleconferences Merck, Speaker for Regional and National Consultants’ meetings Glaxo-Wellcome, National Pulmonary Advisory Committee ABC News, National Respiratory Disease Consultant Gallup Poll, National Allergy and Pulmonary Consultant America’s Health Network (AHN.COM), Allergy and Asthma Consultant DiseaseNet.com WebEBM.com American Academy of Allergy and Immunology to establish national quality of life guidelines for rhinitis Medical Business Development Vanderbilt Asthma Sinus Allergy Program, Founder and Chief Operating Officer Comprehensive airways clinic - started in 1997 and currently with $3,500,000 annual billings Breathe America, Inc. Founding Physician. Airways management company. Capitalized at $7,000,000. Patent holder - Assay of cyclosporin pharmacology, 1999.  Reviewer  Journals Editorial Board - Lipids: 1994 - 1996 Associate Editor - Lipids: 1996- date Ad Hoc Reviewer Biochimica et Biophysica Acta Circulation Circulation Research Molecular Pharmacology  New England Journal of Medicine Journal of Biological Chemistry Prostaglandins American Journal of Physiology Journal of Molecular American Review of Respiratory Disease and Cellular Cardiology Lipids  Proceedings of the National Journal of Asthma Academy of Sciences Kidney International Journal of Immunology Southern Medical Journal Biochemical Pharmacology American Journal of Cardiology Books Consultant to the Editors: Goodman & Gilman's The Pharmacological Basis of Therapeutics Organizations National Institutes of Health, National Institute of General Medical Sciences: Ad hoc, corresponding reviewer for Pathology Study Section, 1988. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Reviewer for Institute Scientific Review Group for RFA "Interstitial Cystitis", 1993. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Reviewer for Institute Scientific Review Group for RFA "Interstitial Cystitis", 1994. Veterans Administration: · Merit Review Grants - National level and extramural consultant for research committees of local Veteran Medical Centers 1988-1992. American Heart Association:  Abstract reviewer for national meeting 1989-1992.  National meeting program organizer (member of Subcommittee on Scientific Sessions Program) 1989, 1990  National American Heart Association meeting, 1990.  Chairman of Featured Research session American Lung Association:  Special Review Panel for Asthma Centers 1996 Swiss National Science Foundation - Special reviewer, 1998 Hospital Committees Asthma Team, 1994-1995 Vanderbilt Representative for Asthma Initiative with Institute for Health Improvement, 1995-1997 Vanderbilt Asthma Sinus Allergy Program Operations Committee, 1997 -date Medical School Conflict of Interest Committee, 1998- present Board of Directors Vanderbilt Asthma Sinus Allergy Program Board of Directors, 1997- date  Vanderbilt Medical School Activities Yearly interviewing of medical school applicants Advisor for two medical students in each class during basic science year and an additional one to two students during the clinical years Clinical Responsibilities Attending for the Allergy clinic one full day per week (overseeing 3 fellows, 2 residents in the Ambulatory Care rotation and an occasional medical student seeing over 30 patients) General Internal Medicine Attending at the VA (approximately one month every other year) Inpatient and consultation services Allergy/Immunology year round at Vanderbilt Hospital Asthma Sinus Allergy Program several days a week (overseeing total of 5 nurse practitioners) Medical School Teaching/Training Responsibilities Pharmacology 501 - Medical School Pharmacology Course: Yearly lecture on asthma for second year medical students Pharmacology 325 - Cardiovascular Pharmacology: Biyearly lecture on endothelial - white cell interactions Pharmacology course for graduate students - Physiology: Section on Pulmonary physiology and acid-base Interdisciplinary graduate program - eight week lab rotation for first year graduate students; generally one to two per year Interdisciplinary graduate program - Dissertation committee for graduate students Medicine 610 - Special Studies in Medicine: elective for medical students to work in laboratory - average 1 student for an eight week elective per year  Medicine 544A - Allergy Clinic Elective: Elective for fourth year medical students Pathology 301 - Graduate course for Pathology students. Yearly lecture on Reperfusion Injury.  NIH- sponsored Minority High School Student Research Apprentice Program- Summers 1990&1991  Ambulatory Clinical Elective for Internal Medicine residents - generally one resident per half day allergy clinic  Clinical Elective for Otolaryngology residents - generally one resident a clinic day Research/Laboratory Training for fellows in the Divisions of Allergy, Rheumatology, Pulmonary, Dermatology, Cardiology, Otolaryngology Medical Scholars’ Program at Vanderbilt - mentor Basic and Clinical Research Sponsorships for clinical fellows and/or post-doctoral fellows -1 to 2 per year Research Support National Institutes of Health NIH Doctoral Fellowship. Salary and tuition stipend. 1975-1977.  NIH and Soviet Academy of Sciences Exchange Fellowship. Travel and salary stipend. 1977. NIH Post-Doctoral Fellowship. Salary stipend. 1983-1985.  NIH - NIGMS. Research Center for Pharmacology and Drug Toxicology. (Principal Investigator, John Oates) Principal Investigator of Project IV. "Aspirin-evoked syndromes: Systemic mast cell activation and asthma." ($3,410,784 total). 1987-1992. $462,862 for Project IV. NIH Biomedical Research Support Grant, Vanderbilt University. "Chemical Characterization of Endothelium-Derived Relaxing Factor." Principal Investigator. $7,100. 1988-1989. NIH Biomedical Research Grant, Vanderbilt University. "Phospholipase D activation in human polymorphonuclear cells." Principal Investigator. $8990. 1989-1990. NIH R-29 "Role of circulating cells in glomerular injury." Co-investigator, 5% effort (Principal Investigator, Agnes Fogo). $375,000. 1990-1995. NIH NRSA "Phospholipase D activation in human neutrophils." Sponsor for A.P. Truett, M.D. $88,000. 1990-1994. NIH Biomedical Research Support Grant. Vanderbilt University. "Leukocyte regulation by phosphatidic acid" Principal Investigator. $6,000. 1990-1991. NIH Biomedical Research Support Grant. Vanderbilt University. "Medical vs. surgical treatment of sinusitis exacerbated asthma." Co-investigator. $4,000. 1990- 1991. Office of Biologics, Federal Drug Administration. "Standardization of allergen extracts." Principal Investigator. $4,000. 1991. Office of Biologics, Federal Drug Administration. "Standardization of allergen extracts." Principal Investigator. $2,000. 1992. NIH - NIGMS. Research Center for Pharmacology and Drug Toxicology. (Principal Investigator, John Oates) Principal Investigator of Project IV. "Aspirin-evoked syndromes: Systemic mast cell activation and asthma." ($2,036,285 total). 1992-1995. $413,506 for Project IV. NIH-R01. "Role of adenosine and endothelin in myocardial reperfusion injury." Principal Investigator. $144,000. 1993-1995. NIH - NIGMS. Research Center for Pharmacology and Drug Toxicology. (Principal Investigator, John Oates) Co-investigator-Project 3. "Regulation and mediation of the immune response by eicosanoids: Pharmacology of PGE2 in human asthma." ($4,062,509 total). 1996-2001. $1,075,074 for Project 3. Office of Biologics, Federal Drug Administration. "Standardization of latex allergen extracts." Principal Investigator. $8,000. 1995-1996. NIH-R01. "RFA for Asthma Center” In preparation for 1/1/01. NIH-R01. "Signal transduction mechanisms of inflammatory/immune cells: Effects of electromagnetic fields" Principal Investigator. Submitted. Non-Federal support - Competitive awards or investigator initiated  Vivian Allen M.D.-Ph.D. Award. Salary and tuition stipend. 1977-1979. Pfizer Post-Doctoral Fellowship. "Investigation of a Leukotriene Epoxide in the Activation of a Unique Inflammatory Granulocyte." $105,000. 1984-1988. RJ Reynolds Award. "Investigations on the Activation of the 5-Lipoxygenase in White Blood Cells." Principal Investigator. $25,000. 1986-1987. RJR Nabisco Scholars Award. $225,000. 1987-1990.  North Carolina Lung Association. "Studies on the Mechanism of Sulfite Sensitivity." Principal Investigator. $10,000. 1988-1989. University Research Council Grant, Vanderbilt University, "Effects of antihistamines on the histamine metabolism." Principal Investigator. $9,146. 1989-1990. University Research Council Grant, Vanderbilt University. "Mechanism of enhanced releasibility of histamine in mast cell diseases." Principal Investigator $9,396. 1990-1991. Alpha Pharmaceuticals. "Effects of Fluosol on Neutrophil function." Principal Investigator. $22,000. 1990-1991. Searle. "Efficacy of SC-45662 on allergic rhinitis during antigen challenge." Principal Investigator. $75,000. 1990-1991. American Cancer Society. "Cell Regulation by phospholipase D pathway." Principal Investigator. $10,000. 1991-1992. Searle Arthritis and Prostaglandin Challenge. "Modulation of human leukocyte function by misoprostol." Principal Investigator. $145,000. 1991-1993. Abbott Laboratories. "Effects of A-64077 on BAL eicosanoids." Principal Investigator, $7500. 1992. Burroughs-Wellcome. "Mechanism of RheothRX on neutrophil function." Principal Investigator. $15,000. 1993. Searle. "Pharmacology of Misoprostol." Co-Principal Investigator. $238,700. 1993- 1995. Abbott Pharmaceuticals. "Inhibition of leukotriene production by human alveolar macrophages with zileuton." Principal Investigator. $4,000. 1994-1995.  Glaxo. "The anti-inflammatory effect of salmeterol on the late phase response to segmental antigen challenge." Principal Investigator. $75,000. 1994-1995.  GlaxoWellcome. “Comparison of Flovent vs. Accolate on Airway Reactivity.” Principal Investigator. $50,000, 1997-1998.  Chest Foundation. “Effects of levalbuterol on asthmatic late phase inflamation” Mentor for Fellow award, $10,000, 2000-2001 Searle SC58635, Clinical Protocol for a Multicenter, Double-Blind, Placebo, Controlled, Randomized, Crossover with Open Label Rechallenge Study of the Safety of Multi doses of SC-58635 Oral Fine Suspension and 200mg Capsule in Aspirin Sensitive Asthma. $79,510 2000- Sepracor. “Effects of levalbuterol on bronchoalveolar lavage following antigen challenge”, Principal Investigator, $58,000/. 2000- GlaxoWellcome. “Comparison of fluticasone and montelukast on airway remodeling in asthma”, Principal Investigator, $75,000. 2000-  American Collage of Chest Physicians. “Effects of levalbuterol on inflammatory changes in asthma”, Sponsor for John Overholt, MD, Fellowship award $10,000. 2000-2001 Smith Kline Beecham. Effects of anti-IL5 on aspirin sensitive asthma. Pharmaceutical - basic and clinical research funding Abbott Laboratories. "Effects of A-64077 on seasonal allergic rhinitis" Co-principal investigator. $240,000. 1989. Abbott Laboratories. "Effects of A-64077 on moderate asthma." Principal Investigator. $60,000, 1990-1991. Greer Laboratories. "Evaluation of DermaPIK" Principal Investigator. $2,000. 1990. Abbott Laboratories. "Effects of A-64077 on seasonal allergic rhinitis" Co-principal investigator. $85,000. 1990. Greer Laboratories. "Standardization of American cockroach extracts." Principal Investigator. 1,000. 1990. Greer Laboratories. "Standardization of cat extracts." Principal Investigator. $2,000. 1990.  Pfizer. "Evaluation of cetirizine in allergic rhinitis." Principal Investigator. $2,500. 1990.  Ciba-Geigy. "Formoterol in chronic asthma." Principal Investigator. $128,000. 1991-1992. Greer Laboratories. "Standardization of extracts of three cockroach species." Principal Investigator. $5,000. 1991. Greer Laboratories. "Relative potency studies of cockroach antigens." Principal Investigator. $6000. 1991-1993 Greer Laboratories. "Grass pollen skin test study." Principal Investigator. $2,000. 1991. Greer Laboratories. "Comparison of multiple lots of Candida albicans skin test antigen." Principal Investigator. $2,000. 1992. 3M Pharmaceuticals. "Evaluation of metered dose inhaler technique." Principal Investigator. $10,000. 1992. Abbott Laboratories. "Zileuton vs. theophylline or placebo in moderate asthma." Principal Investigator. $60,000. 1992-1993. Rhone-Poulenc Rorer Pharmaceuticals. "Efficacy of Nasacort in perennial non-allergic rhinitis." Principal Investigator. $26,500. 1992.  Abbott Laboratories. "Zileuton in moderate asthma." Principal Investigator. $55,000. 1991-1992. Merck Pharmaceuticals. "MK-0591 5-lipoxygenase inhibitor in asthma." Principal Investigator. $69,000. 1992-1993. ICI/Zeneca Pharmaceuticals. "Leukotriene antagonist in asthma." Principal Investigator. $95,000. 1993. Merck Pharmaceuticals. "MK-0479 a leukotriene antagonist in asthma." Principal Investigator. $65,000. 1993. TAP Pharmaceuticals. "Thromboxane/PGD2 antagonist in asthma." Principal Investigator. $75,000. 1993. ICI/Zeneca Pharmaceuticals. "Accolate dose ranging study in chronic asthma." Principal Investigator. $80,000. 1993. ICI/Zeneca Pharmaceuticals. "Leukotriene antagonist in steroid dependent asthma." Principal Investigator. $85,000. 1993. Abbott Laboratories. "5-Lipoxygenase inhibitor in aspirin-sensitive asthma." Principal Investigator. $65,000. 1994. Janssen. "Hismanal dose ranging study." Principal Investigator. $80,000. 1994. Ciba-Geigy. "Formoterol in chronic asthma: Pharmacology of film delivery device." Principal Investigator. $225,000. 1994-1995. Rhone-Poulenc Rorer Pharmaceuticals. "Effects of an aqueous based triamcinolone inhaler on seasonal allergic rhinitis." Principal Investigator. $40,000. 1994. Zeneca Pharmaceuticals. "Analysis of leukotrienes in nasal lavage." Principal Investigator. $325,000. 1993-1995. Glaxo Pharmaceuticals. "Efficacy and quality of life outcomes of Salmeterol treatment in asthma." Principal Investigator. $25,000. 1994-1995. Smith Kline and French. "Effects of a leukotriene antagonist in asthma." Principal investigator. $70,000. 1994-1995. Greer Laboratories. "Comparison of Multiple Lots of CASTA", "CASTA dose response study", and "Grass pollen skin test study". Principal Investigator for all. Submitted for 1994-1995.  Abbott Pharmaceuticals. "Long term surveillance study of Zileuton versus usual care in patients with asthma." Principal Investigator. $30,000. 1994-1995. Jansen Pharmaceuticals. "Long-term safety of levacobastine nasal inhaler." Principal Investigator. $100,000. 1995. Takeda Abbott Pharmaceuticals. "Safety and efficacy of AA-2414 in moderate asthma." Principal Investigator. $60,000. 1995. Glaxo Research Institute. "Long-term safety of salmeterol via Diskus in asthma." Principal Investigator. $100,000. 1995. Searle Pharmaceuticals. "Pharmacokinetics of oral and intravenous misoprostol." Principal Investigator. $104,000, 1995. Rhone Poulenc Rorer Pharmaceuticals. "Efficacy of Azmacort-Forte in asthma." Principal Investigator. $60,000, 1995. Glaxo Pharmaceuticals. "Comparison of salmeterol vs. beclomethasone in asthma." Principal Investigator. $60,000, 1995.  Glaxo Pharmaceuticals. "Effect of salmeterol and beclomethasone on airway reactivity." Principal Investigator. $70,000. 1995. Takeda Abbott Pharmaceuticals. "Effect of AA-2414 on isoprostane levels in smokers with moderate asthma." Principal Investigator. $70,000. 1995. Fissons Pharmaceuticals. "Safety and efficacy of alternate propellants for Tilade." Principal Investigator. Submitted, 1995. Ciba-Geigy Pharmaceuticals. "Safety and efficacy Irulakast, an inhaled leukotriene antagonist in asthma." Principal investigator. $225,000. 1995-1996. Zeneca Pharmaceuticals. "Safety and efficacy of Accolate in mild to moderate asthma." Principal investigator. $119,000. 1995-1997. Hoeschst-Roussell Marion Pharmaceuticals. "Safety and efficacy of terfenadine metabolite in seasonal allergic rhinitis." Principal investigator. $32,000. 1996. Otsuka America Pharmaceutical. "Efficacy of OPC-17116 in community acquired pneumonia." Principal investigator. 1995. Glaxo - Wellcome Pharmaceuticals. "Comparison of fluticasone to beclomethasone in the treatment of asthma. Principal investigator. $52,000. 1995-1996. GlaxoWellcome Pharmaceuticals. "Comparative Trial Evaluating Fluticasone Propionate, Triamcinolone Acetonide, or Fluticasone Propionate in Combination with Salmeterol Xinafoate in Subjects with Asthma Who Remain Symptomatic Despite Receiving Inhaled Corticosteroids." Principal Investigator. $40,000. 1996 Schering Plough - "Long Term Safety Study of Mometasone Furoate Dry Powder and Beclomethasone Dipropionalte (Vanceril®) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids." Principal Investigator. $54,000. 1996. Schering-Plough - "Safety and Efficacy of Claritin-D 24 Hour vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis (SAR) Protocol ." Principal Investigator. $54,000. 1996. Janssen - "Itraconazole vs. Placebo in the Adjunctive Treatment of Corticosteroid-Dependent Allergic Bronchopulmonary Aspergillosis: A Multicenter, Prospective, Randomized, Double-blind Clinical Trial." Principal Investigator. $37,650.00. 1996 to 1997 Schering Plough - "Long Term Safety Study of Mometasone Furoate Dry Powder and Beclomethasone Dipropionate (Vanceril®) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta Agonists Alone." Principal Investigator. $49,000. 1997 - Rhone Poulenc Rorer - “Comparison of efficacy an safety of Ebestine vs. Loratadine in seasonal allergic rhinitis.” Principal Investigator. $60,000. 1997.  Smith Kline - “ Dose ranging, efficacy and safety of an endothelin antagonist on pulmonary hemodynamics and clinical response in moderate to severe COPD.” Principal Investigator. $77,850. 1997 Schering Plough - "Long Term Safety Study of Mometasone Furoate HFA 227 and Beclomethasone Dipropionate (Vanceril®) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Steroids. Principal Investigator, 1998. SmithKline - "A Repeat-Dose, Dose-Ranging, Placebo-Controlled Study of the Safety and Efficacy of SB 210396 (anti-CD4) in Patients with Chronic Severe Asthma." Principal Investigator. 1998. Smith Kline - “ Dose ranging, efficacy and safety of an endothelin antagonist on pulmonary hemodynamics and clinical response in severe COPD requiring oxygen.” Principal Investigator. $168,000. 1998 GlaxoWellcome - “ Evaluation of the safety and efficacy of fluticasone HFA227 in steroid dependent asthmatics.” Principal Investigator. 1998. Covance/GlaxoWellcome.- “ Surveillance study of asthma event outcomes in subjects treated with Serevent.” Principal Investigator. 1998. Novartis - “Randomized, between-patient trial comparing two doses of inhaled formoterol fumarate drypowder (12 ug and 24 ug) with placebo (double blind) and with oral slow-release theophylline at individual doses based on serum levels (open-label), each administered twice daily for one year to patients with chronic obstructive pulmonary disease in terms of clinical efficacy, tolerability and quality of life.$106,535.00 1997-1999. Glaxo-Wellcome - A double-blind, double-dummy, randomized, placebo-controlled, parallel-group comparison of Fluticasone propionate aqueous nasal spray and triamcinolone acetonide aqueous nasal spray in subjects with seasonal allergic rhinitis. $33,000.00. 1997-1998. Schering-Plough - A Double-Blind Placebo-Controlled Study to Evaluate the Effects of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (For Asthma and SAR). 1998-1999.  Schering-Plough -A Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of Claritin® vs. Allegra in the Treatment of Subjects with Seasonal Allergic Rhinitis. $60,000. 1998-1999. Schering-Plough -Safety and efficacy of Claritin in lessening the Severity of Asthma Exacerbation Associated with Seasonal Allergic Rhinitis. $66,000. 1998-1999. Abbott-Laboratories - Comparative Study of the Safety and Efficacy of Clarithromycin Immediate Release and Clarithromycin Extended Release in the Treatment of Acute Maxillary Sinusitis in Adults. $26,000. 1998-1999. Abbott-Laboratories - A Comparative Study of the Efficacy of Clarithromycin and Azithromycin for the Treatment of Patients with Acute Exacerbation of Chronic Bronchitis. 1998-1999.  Abbott-Laboratories A Comparative Study of the Efficacy and Safety of Clarithromycin Immediate Release Tablets and Loracarbef Pulvules for the Treatment of Subjects with Secondary Bacterial Infections of Acute Bronchitis. 1998 -1999. Glaxo Wellcome - A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 44 mcg BID or 88mcg BID versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid-Dependent Asthmatics. $60,000. 1998-2000. Novartis: Randomized, parallel-group, open-label Multicenter clinical study comparing the safety, efficacy, quality of life and socioeconomic variables of twice daily formoterol powder (12ug bid) to twice daily salmeterol (50ug bid) administered for six months to adult subjects with reversible obstructive airway disease (ROAD). $10,000 1998-1999 Forrest: A Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel Trial Evaluating the efficacy and Safety of HFA Flunisolide Vs CFC flunisolide in Pediatric Patients with Mild to Moderate Asthma. $64,480 1998 - 1999 Novartis: Randomized, between patient trial comparing two doses of inhaled formoterol fumarate dry powder (12 ug and 24 ug) with placebo (double-blind) and with oral slow-release theophylline at individual doses based on serum levels (open-label), each administered twice daily for one year to patients with chronic obstructive pulmonary disease in terms of clinical efficacy, tolerability and quality of life. $112,535 1998-on going Pfizer: A Second Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy, Safety, and Effect on Quality of Life of Zyrtec (Cetirizine HCI) vs. Placebo in the Treatment of Seasonal Allergic Rhinitis. $26,741 1999-on going Glaxo Wellcome: A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50 mcg BID) With Oral Montelukast (10 mg QD) In Subjects With Persistent Asthma Symptomatic On Concomitant Inhaled Corticosteroid Therapy. $31,200 1999-on going Glaxo Wellcome: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the Diskus Formulations of Salmeterol 50mcg BID and fluticasone Propionate 500mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects. $75,564 1999-on going. Immunex: Phase II Efficacy Study of Aerosolized Recombinant Human IL –4 Receptor in Asthma. $106,130 1999-on going Schering Plough: A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Budesonide DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids. $49,490 1999-on going Glaxo Wellcome: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study Of Inhaled Fluticasone Propionate (88MCG BID) Versus Montelukast Sodium (10MG QD), In Subjects Currently Receiving Beta Agonists Alone” $56,000 1999-on going Janssen: A Double-Blind Placebo Controlled Pilot Trial to Determine the Efficacy of Cisapride in Improving Respiratory Symptoms and Pulmonary function in Asthmatics with Gastroesophageal Reflux (GER). $79,212 1999-on going Merck 102-00: A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis who Have a History of Asthma. $95,800 1999-on going Merck MK088-01: A Double-Blind Randomized, Stratified, Parallel-Group Study to Assess the Incidence of PUB’s during Chronic Treatment with MK-0966 or Naproxen in Patients with Rheumatoid Arthritis. Co-Investigator $61,800 1999-on going Glaxo Wellcome EXP10001: A Multi-Center Study to Investigate Genetic Polymorphism’s in Subjects with Severe Asthma Dependent on Daily doses of Oral Corticosteroids $5,000 2000-on going Glaxo Wellcome SAS30017: A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol 50mcg/Fluticasone Propionate 100mcg DISKUS- Combination Product BID Compared With Salmeterol 50 mcg via DISKUS- BID and Fluticasone Propionate 100mcg via DISKUS- BID in Symptomatic Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy. $60,168 2000-on going HMR 4003B/4001: A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated with Risedronate. $59,100 2000 -on going Sepracor 110-029: A Twelve-Month Safety Study of 90mg Norastemizole QD in Subjects with Perennial Allergic Rhinitis/Seasonal Allergic Rhinitis. $69,345 2000-on going Merck SNG477, A Randomized, Double-Blind, Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics. $62,712 2000-on going SmithKline Beecham 551, An Open, Non-Comparative, Multicentre Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis (ABS) in Adults.$40,950 2000-on-going Glaxo Wellcome FPD40009, A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subject Greater than 12 Years of Age with Chronic Asthma $36,400 2000 – on going Merck 162-00, A Multicenter, Double blind, Parallel-Group Study Investigation the Clinical effect of Combination Montelukast/Loratadine in Patients with seasonal Allergy Rhinitis-spring Study $78,999 2000-on going Pfizer 1462, A randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine-Pseudoephedrine vs. Fexofenadine-Pseudoephedrine (Allergra-D) vs. Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis $55,076 2000-on going Immunex, Dose response of Nuvance, a soluble, inhaled IL-4 receptor in asthma. 2000. Schering-Plough, A dose ranging trial of Desloratadine in seasonal allergic rhinitis, 2000. Invited Presentations (representative) Clinical  The University of Arkansas in Jonesboro, Arkansas The University of Tennessee in Knoxville, Tennessee The University of Alabama in Huntsville, Alabama Marshall University in Huntington, West Virginia Deaconess Hospital in Evansville, Indiana Park West Hospital in Knoxville, Tennessee Veterans Administration Hospital in Murfreesboro, Tennessee The Kentucky Allergy Society annual meeting in Louisville, Kentucky Wellborn Baptist Hospital in Evansville, Indiana The Nashville Medical Society in Nashville, Tennessee Baptist Hospital in Nashville, Tennessee Redstone Arsenal Hospital in Huntsville, Alabama Fort Sanders Hospital in Knoxville, Tennessee University of Tennessee Internal Medicine Program at the Jackson Clinic in Jackson, Tennessee Southeast Regional Allergy Fellows Training Course Cheatham County Medical Center, Ashland City, TN Louisiana State Society of Family Medicine, Nashville, TN Clarkesville Memorial Hospital, Clarkesville, TN St. Francis Hospital in Charleston, WV Southeastern Allergy Society at Sea Island, GA Georgia Baptist Medical Center in Atlanta, GA Veterans Administration Hospital in Murfreesboro, TN Saint Thomas Hospital, Nashville, TN East Tennessee Medical School at Johnson City  Allergist Society, Kentuciana meeting at Louisville, KY Tennessee Thoracic Society Annual Meeting, Nashville, TN Pine Lake Hospital at Mayfield, KY Allergist Society, Lexington, KY Deaconess Hospital at Evansville, IN Coffeyville Hospital at Coffeyville, KS Kansas City medical society, Kansas City, KS Middle Tennessee Nurses Association at Nashville, TN Jackson Clinic, Jackson, TN Gainesville Internal Medicine Society, Florida Children’s Hospital, Austin, Texas Meharry Medical School, Nashville, TN Massachusetts Medical Society Asthma Symposium, Symposium Director, Brentwood, TN  West Virginia Annual Family Practice Meeting, Charleston, WV Orlando Regional Medical Center, Orlando, FL Trinity Lutheran Hospital, Kansas City, MO Central Kansas Medical Center, Great Bend, KS Geary County Community Hospital, Junction City, KS Annual meeting of the Otolarngological Society, Phoenix, AR Medical Society, Houston, TX Medical Society, Little Rock Arkansas Rush Presbyterian Hospital, Chicago, IL Louisiana Allergy Society Annual Meeting, New Orleans, LA Huntsville Hospital, Huntsville, AL East Virginia Medical Center, Richmond, VA Southeastern regional teleconference speaker on Allergic Rhinitis Internal Medicine Meeting, St. Louis, MO University of Tennessee Annual Pulmonary meeting, San Destin, FL Alabama Allergy Society, Annual meeting, San Dentin, FL Pulmonary/Allergy consultants meeting, Baltimore, MD GlaxoWellcome Speaker at National Speaker Training Courses for Consultants, Palm Springs, Marco Island, New York City, Newport Beach, Orlando, Laguna Beach Consumer Advisory Panels with allergy/pulmonary specialists - Charlotte, Houston, Nashville, Boston Medical society meeting - San Juan, Puerto Rico Medical Society meeting - Buenos Aires, Argentina Pediatric Grand rounds - Scottish Rite Hospital, Atlanta, GA KickAsthma Summit - American Lung Associations of Kentucky and Tennessee, Bowling Greene Allergy meeting - University of Pittsburgh, Pittsburgh, PA Texas Academy of Family Practice - Austin, TX Virginia State Allergy Association - Virginia Beach, VA Louisiana State Allergy Association - New Orleans, LA Medical Grand rounds - Jacksonville Naval Hospital, Jacksonville, FL National teleconferences (moderator/speaker) for Pfizer on treatment of allergic rhinitis National teleconferences (moderator/speaker) for GlaxoWellcome on treatment of asthma National teleconferences (moderator/speaker) for Merck on leukotriene modulators in asthma therapy National video conference (speaker) for Annenberg Center for Health Sciences on treatment of asthma Delaware Allergy Society Delaware Lung Association annual meeting Medical College of Pennsylvania/Hahnemann, Pulmonary Grand Rounds CME Course Director - Academy of Pediatrics and several Primary Medicine national meetings  Eastern Tennessee Lung association annual meeting, Bristol County Hospital, Bristol City, TN Ohio Allergy Society annual meeting Greater Washington Allergy Society annual meeting Arkansas Lung Association Annual meeting New Hampshire Lung Association Annual meeting Research Alliance Pharmaceuticals at San Diego, California Burroughs Wellcome at Research Triangle Park, North Carolina Merck Frosst at Montreal, Canada Prostaglandin Meetings at Keystone, Colorado Biophysical Society Meeting at Baltimore, Maryland Southeastern Allergy Society annual meeting at Hilton Head, South Carolina American Society of Clinical Pharmacology annual meeting at Nashville, Tennessee Pfizer at Sandwich, England  British Endocrine Society at London, England Searle Pharmaceutical sponsored national research symposium at Chicago, IL-Keynote address International Respiratory Symposium at London, England Henry Ford Hospital in Detroit, Michigan Glaxo- Burroughs Wellcome in Raleigh Durham, North Carolina Glaxo-Burroughs Wellcome at London, England American Academy of Allergy Asthma and Immunology - San Francisco, CA Inter-Mountain Thoracic Society - Salt Lake City, Utah American Thoracic Society - Chicago, IL  American Academy of Allergy Asthma and Immunology - Washington, DC North Carolina Thoracic Society - Chapel Hill, NC Joint Transpacific US-Japan Asthma meeting, Honolulu World Asthma meetings, Barcelona, Spain European Respiratory Society, Florence Italy Transatlantic Allergy Society, Australia Continuing Medical Education Presentations Sponsored by Vanderbilt Family Medicine Update Drug Therapy for the Practicing Internist Functional Endoscopic Sinus Surgery Course (given twice a year) Rhinoscopy for the Internist Tennessee Society of Clinical Pathology Technologists Multiple presentations to local medical societies and hospitals CME Course director for numerous national conferences - Academy of Pediatrics, Family Practice, Internal Medicine Clinical or Research Presentations at Vanderbilt Medicine Grand Rounds Medical Research Conference  VA hospital morning report for medicine house staff and medical students Conferences in: Department of Medicine including Divisions of Clinical Pharmacology, Allergy/Immunology, Pulmonary and Critical Care Medicine, Nephrology, Rheumatology/Immunology, Neurology, Cardiology  Department of Pediatrics including Divisions of Pulmonary and Nephrology  Department of Microbiology/Immunology Department of Pathology Department of Otolaryngology  Publications Original Articles Murray JJ, PW Reed and FS Fay. Contraction of isolated smooth muscle cells by ionophore A23187. Proc Nat Acad Sci USA 72:4459-4463, 1975.  Levitsky DO, JJ Murray, AV Lebedev, SI Zakharov, LV Rozenshtraukh, AV Kuzmin and TV Birjukova. Ca2+ transfer through lipid membranes and changing of contractility of papillary muscle induced by antibiotic A23187. Bull Natl Res Center Cardiol Acad Med Sci USSR 1:31-40, 1978. Zakharov SI, JJ Murray, DO Levitsky and LV Rozenshtraukh. Effects of ionophore A23187 on contraction and the action potential of guinea pig papillary muscle. Bull Exp Biol Med 85:690-693, 1978.  Murray JJ. Effects of divalent cation ionophore A23187 on cardiac contractile and biochemical parameters. Doctoral Dissertation, Vanderbilt University, 1979.  Murray JJ, FA Greco, SN Wolff and JO Hainsworth. Neoplastic meningitis: marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 75:289-294, 1983. Murray JJ, FA Greco, SN Wolff and JO Hainsworth. Neoplastic meningitis. Archives Vanderbilt Housestaff. 133-139, 1983  Murray JJ, CA Clark, RH Lands, CR Heim and LS Burnett. Reactivation blastomycosis presenting as a tubo-ovarian abscess. Obst Gynec 64:828-830, 1984.  Murray JJ and CR Heim. Hypercalcemia in disseminated histoplasmosis: aggravation by vitamin D. Am J Med 78:881-884, 1985.  Murray JJ, JG Dobson and PW Reed. Effects of divalent cation ionophore A23187 on cardiac contractile parameters. Am J Physiol 249 (Heart Circ Physiol 18): H1195-H1203, 1985.  Murray JJ, PW Reed and JG Dobson. Biochemical changes accompanying enhanced cardiac contractility by ionophore A23187. Am J Physiol 249 (Heart Circ Physiol 18): H1204-1210, 1985.  Murray JJ, AV Kuzmin, PW Reed and DO Levitsky. Low concentrations of A23187 Ca2+ uptake by cardiac sarcoplasmic reticulum. Am J Physiol 249 (Heart Circ Physiol 18): H1211-1215, 1985.  Brash AR, JJ Murray and JA Oates. The 5-lipoxygenase and 15-lipoxygenase of neutrophils and eosinophils. In Leukotrienes in Cardiovascular and Pulmonary Function. Eds AM Lefer and MH Gee, Alan R. Liss, Inc., New York, 143-152, 1985.  Murray JJ and MC Houston. Multiple calcified intracranial metastases from breast carcinoma with a therapeutic response to tamoxifen. South Med J 79:253-254, 1986. Murray JJ, AB Tonnel, AR Brash, L J Roberts II, P Gossett, R Workman, A Capron and JA Oates. Prostaglandin D2 is released during acute bronchospasm in man. Trans Assoc Am Physicians 98:275-280, 1986.  Murray JJ, AB Tonnel, AR Brash, L J Roberts II, P Gossett, R Workman, A Capron and JA Oates. Release of prostaglandin D2 into human airways during acute antigen challenge. New Eng J Med 315:800-804, 1986.  Murray JJ, I Fridovich, RG Makhoul and P-O Hagen. Stabilization and partial characterization of endothelium-derived relaxing factor from cultured aortic endothelial cells. Biochem Biophys Research Commun 141:689-696, 1986.  Nowak J, JJ Murray, GA FitzGerald, CJ Wehr, JW Hammon and JA Oates. Eicosanoids and sudden cardiac death. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 17. Eds B Samuelson, R Paoletti and PW Ramwell, Raven Press, New York, 20-24, 1986.  Fridovich I, P-O Hagen and JJ Murray. Endothelium-derived relaxing factor (EDRF): In search of the endogenous nitroglycerin. News in Physiological Sci 2:61-64, 1987.  Dillon SB, JJ Murray and R Snyderman. Identification of a novel inositol bisphosphate isomer formed in chemoattractant stimulated human polymorphonuclear leukocytes. Biochem Biophys Research Commun 144:264-270, 1987.  Nowak J, JJ Murray, JA Oates and GA FitzGerald. Biochemical evidence of a chronic abnormality in platelet function of apparently healthy cigarette smokers. Circulation 76:6-14, 1987.  Dillon SB, JJ Murray, MW Verghese and R Snyderman. Regulation of inositol phosphate metabolism in chemoattractant-stimulated human polymorphonuclear leukocytes: Definition of distinct dephosphorylation pathways for IP3 isomers. J Biol Chem 262:11546-11552, 1987.  Cross KSH, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Endothelium derived relaxing factor (EDRF) production is absent in vein grafts. Surgical Forum 38:319-321, 1987. Hawkins DJ, BO Meyrick and JJ Murray. Activation of guanylate cyclase and inhibition of platelet aggregation by endothelium-derived relaxing factor released from cultured endothelial cells. Biochim Biophys Acta 969:289-296, 1988.  Dillon SB, JJ Murray, RJ Uhing and R Snyderman. Regulation of inositol phospholipid and inositol phosphate metabolism in chemoattractant-activated human polymorphonuclear leukocytes. J Cell Biochem 35:345-361, 1987. Thompson KA, JJ Murray, IA Blair, RL Woosley and DM Roden. Plasma concentrations of quinidine, its major active metabolites and dihydroquinidine in patients with Torsades de Pointes. Clin Pharmacol Therap 43:636-642, 1988. Cross KSH, MN El-Sanadiki, JJ Murray,EM Mikat, RL McCann and P-O Hagen. Functional abnormalities of experimental autogenous vein graft neoendothelium. Annals Surgery 208:631 638, 1988. Cross KSH, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Mast cell infiltration: A possible mechanism for vein graft vasospasm. Surgery 104:171-177, 1988.  Murray JJ and AR Brash. Rabbit reticulocyte lipoxygenase catalyses specific 12(S) and 15(S) oxygenation of arachidonoyl - phosphatidylcholine. Arch Biochem Biophys 265:514-523, 1988.  El-Sanadiki MN, KS Cross, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Verapamil reduces intimal hyperplasia in experimental vein bypass grafts. Surgical Forum 39:326-328, 1988. El-Sanadiki MN, KS Cross, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Normal endothelial function and decreased vasoreactivity of experimental arterial grafts. J Vasc Surg 9:98-106, 1989. Badr KF, JJ Murray, MD Breyer, K Takahashi, T Inagami and R Harris. Mesangial cell, glomerular and renal responses to endothelin in the rat kidney: Elucidation of signal transduction pathways. J Clin Invest 83:336-342, 1989. Truett AP III, R Snyderman and JJ Murray. Stimulation of phosphatidylcholine turnover and diacylglycerol production in human polymorphonuclear leukocytes: Novel assay for phosphorylcholine. Biochem J 260:909-913, 1989.  Murray JJ. Asthma sprays to the rescue. Health Confidential, 1989. Chu A, FR Cobb, P-O Hagen and JJ Murray. Effects of stabilized endothelium-derived relaxing factor on coronary vasculature in awake dogs. Am J Physiol (Heart Circ Physiol), 257:H1895-1899, 1989. El-Sanadiki MN, KS Cross, JJ Murray, E Mikat, RL McCann and P-O Hagen. Reduction of intimal hyperplasia and enhanced reactivity in experimental vein bypass grafts with verapamil treatment. Annals Surgery, 212:87-96, 1990.  Murray JJ, TT Dinh, AP Truett III and DA Kennerly. Isolation and enzymatic assay of choline and phosphorylcholine present in cell extracts with picomole sensitivity. Biochem J, 270:63-68, 1990. Chu A, JJ Murray, C-C Lin, M Russell, P-O Hagen and FR Cobb. Preferential proximal coronary artery dilation by activators of guanylate cyclase in awake dogs. Am J Physiol (Heart Circ Physiol) 259: H340-H345, 1990. Murray JJ, J Nowak, JA Oates and GA FitzGerald. Platelet-vascular interaction during chronic smoking in man. Advances Exper Med Biol 273: 189-198, 1990. Sasaki K, Y Yamano, S Bardhan, N Iwai, JJ Murray, M Hasegawa and T Inagami. Cloning and expression of a cDNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351: 230-233, 1991. El-Sanadiki MN, KS Cross, JJ Murray, RW Schuman, E Mikat, RL McCann and P-O Hagen. Reduction of intimal hyperplasia and enhanced reactivity of experimental bypass grafts with verapamil treatment. Ann Surg 213:374-75, 1991. Gay JC and JJ Murray. Differential effects of propranolol on responses to receptor-dependent and receptor-independent stimuli in human neutrophils. Biochim Biophys Acta 1095:236-242, 1991.  Inagami T, K Sasaki, N Iwai, Y Yamano, S Bardhan, F Konishiih, S Chaki, JJ Murray, and M Hasegawa. Cloning and Characterization of Angiotensin II Receptor and Its Regulation in Bovine Adrenocortical Cell and Rat Kidney. J Vasc Med Biol 3:192-196, 1991. Forman MB, CJ Pitarys, H Hildibil, T Lambert, DA Ingram, R Vermani and JJ Murray. Pharmacologic perturbation of neutrophils by Fluosol-DA results in a sustained reduction of canine myocardial reperfusion injury. J Amer Coll Cardiol 19:205-16, 1992.  Hagen P-O, RW Schuman, MG Davis and JJ Murray. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 29:405-409, 1992. Ingram DA, MB Forman, and JJ Murray. Phagocytic activation of human neutrophils by the detergent component of Fluosol®. Am J Path 140:1081-1087, 1992. Truett AP III, SB Bocckino and JJ Murray. Regulation of phosphatidic acid phosphohydrolase activity during stimulation of human polymorphonuclear leukocytes. FASEB J, 6:2720-2725, 1992. Forman MB, DA Ingram and JJ Murray. Attenuation of myocardial reperfusion injury by perfluorochemical emulsions. J Clin Hemorheology, 12:121-140, 1992. Forman MB, DA Ingram and JJ Murray. Role of perfluorocarbon emulsions in the treatment of myocardial reperfusion injury. Am Heart J 124:1347-1357, 1992. Murray JJ. Cockroaches may play a role in triggering allergic reactions. Indoor Air Quality Update 5(12):4, 1992.  Ingram DA, MB Forman and JJ Murray. Activation of complement by Fluosol attributable to the pluronic micelle structure. J Cardiovascular Pharmacol 22:456-461, 1993. Hagen P-O, RW Schuman, MG Davis and JJ Murray. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 30:240, 1993. Israel E, P Rubin, J P Kemp, J Grossman, W Pierson, SC Siegel, D Tinkelman, JJ Murray, W Busse, AT Segal, J Fish, HB Kaiser, D Ledford, S Wenzel, R Rosenthal, J Cohen, H Pearlman and JM Drazen. The effect of inhibition of 5-lipoxygenase by Zileuton in mild to moderate asthma. Ann Intern Med 119:1059-1066, 1993. Mullins MD, JJ Murray and WE Serafin. Severe bronchospasm: When aspirin is the cause. Drug Therapy, 24:20-28, 1994.  Mullins MD, JJ Murray and WE Serafin. Respiratory complications of aspirin therapy. Pharmacy and Therapeutics 19:616-630, 1994 Cross KS, MG Davies, MN El-Sanadiki, JJ Murray, EM Mikat, and P-O Hagen. Long-term human vein graft contractility and morphology: A functional and histopathological study of retrieved human coronary vein grafts. Br J Surgery 81:699-705, 1994. Knapp HR and JJ Murray. Leukotrienes as mediators of nasal inflammation. Adv Prostaglandin Thromboxane Research, 22:279:288, 1994. Feoktiskov I, JJ Murray and I Biaggioni. Positive modulation of intracellular Ca2+ by adenosine A2b, prostacyclin and prostaglandin E, receptors via a cholera toxin-sensitive mechanism in human erythroleukemia cells. Molec Pharmocol 45:1160-1167, 1994. Velasco CE, M Turner, T Kondo, T Inagami, JB Atkinson, R Virmani, EK Jackson, JJ Murray and MB Forman. Enhanced local endothelin release following myocardial ischemia and reperfusion contributes to "no-reflow" phenomenon. Am Heart J 128:441-51, 1994. Murray JJ, MD Mullins, HR Knapp, SL Keeler, WE Serafin, B Keane, LJ Roberts II, BJ Struthers and JA Oates. Regulation of the immune response by eicosanoids: Pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. Am J Therapeutics 2:739-748, 1995. Cox JB, R Snyderman and JJ Murray. In vitro inhibition of 5-lipoxygenase activation and translocation in human neutrophils by colchicine. Biochim Biophys Acta, accepted with revision. Cox JB and JJ Murray. Translocation of 5-lipoxygenase activity in BAL cells following stimulation with A23187: Comparison of normal and pulmonary fibrosis patients. Am Rev Resp Dis, accepted with revision. Kane GC, M Tolino, M Pollice, C-J Kim, J Cohn, JJ Murray, R Dworski, J Sheller, JE Fish and SP Peters. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins 50:1-18, 1995. Murray JJ, JV Vitola, GL Schaer and MB Forman. Fluosol in myocardial infarction. J Am Coll Cardiol, 25:1742-1743. 1995. Kane GC, M Pollice, C-J Kim, R Dworski, JJ Murray, J Sheller, JE Fish and SP Peters. A controlled trial of the effect of the 5-lipoxygenase inhibitor, Zileuton, on lung inflammation produced by segmental antigen challenge in humans. J Allergy Clin Immunol 97:646-654, 1996. Israel E, J Cohn, L Dube, JM Drazen and the Zileuton Clinical Trial Group (incuding JJ Murray). Effect of treatment with Zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 275:931-936,1996. Murray JJ. Topical Nasal Steroids. Sinus Newsletter, September, 1996. Duncavage JA and JJ Murray. Sinusitis and reactive airways disease: results of surgical management. Ann Otology, Rhinology Laryngology, in press. Vitola JV, MB Forman, JP Holsinger, M Kawana, JB Atkinson, T Quertermous, EK Jackson and JJ Murray. Role of Endothelin in a rabbit model of acute myocardial infarction: Effect of receptor antagonists. J Cardiovasc Pharm 28:774-83, 1996.  Murray JJ. Asthma patients can throw away their inhalers. National Inquirer, Feb 14, 1996. Forman MB and JJ Murray. Pathogenesis and modification of myocardial stunning and reperfusion injury. In: Acute Myocardial Infarction, Second Edition. Eds: BF Gersh and SH Rahimtoola; Chapman & Hall, New York, 502-548, 1997. Vitola JV, JP Holsinger, JB Atkinson, MB Forman and JJ Murray. Inhibition of Neutrophil Activation as a Mechanism for the Reduction of Myocardial Reperfusion Injury by Lidocaine in the Rabbit Model. Am Heart J 133:315-22, 1997. Gay JC, K Radassi, AP Truett III and JJ Murray. Phosphatase activity regulates superoxide anion generation and intracellular signalling in human neutrophils. Biochem Biophys Acta, 1336:243-53,1997. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, DeSanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledfors D, Murray JJ, Segal A, Tinkelman D and Drazen JM. Naturally occurring mutations in the 5-lipoxygenase gene promotter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99:1130-7, 1997. Murray JJ, DD Hagaman, R Dworski, and JR Sheller. Effect of salmeterol and beclomethasone on the late-phase response to segmental allergan challenge in man. International Respir Forum Acute and chronic Inflammation in the respitory tract. 3:88, 1997. Murray JJ. Stepped care management of asthma. Sinus Newsletter, September, 1997 Duncavage JA and JJ Murray. Sinusitis and reactive airway disease: results of surgical management. Trans Am Broncho-esophagological Assoc, 151-155, 1995. Duncavage JA, JA Van Duyne and JJ Murray. Nasal Polyposis. In: Current Therapy in Otolarngology. Ed. GA Gates, Mosby, St. Louis, 366-370, 1998. Oates JA, Murray JJ, Hagaman DD, Sheller JR, Dworski R, Jackson LJ and HR Knapp. The Pharmacology of Prostaglandin E2: Actions in Human Diseases Involving the Mast Cell. In: Eicosanoids, Aspirin, and Asthma. Eds. A Szczeklik, RJ Grylewski, and JR Vane, Marcel Dekker, Inc., New York. pp 253-258, 1998. Radassi K and JJ Murray. Effects of 60 Hz magnetic field exposure on polymorphonuclear leukocyte activation. Biochim Biophys Acta 1472:359-67, 1999 Busse WW, Casale TB, Murray JJ, Petrocella V, Cox F and K Rickard. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. Am J Managed Care 4:1579-87, 1998. Murray JJ, NL Church, WA Anderson, DI Bernstein, SE Wenzel, A Emmett and KA Rickard. Concurrent use of salmeterol with inhaled steroids is more effective than stweroid-dose increases. Allergy Asthma Proc 20:173-180, 1999. Stein CM, JJ Murray and AJJ Wood. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporin effect. Clin Chem 45:1477-84, 1999. Murray JJ. Leukotriene modifier therapy fore rhinitis and nasal polyps. Sinus Newsletter. 1999.  Radassi K and JJ Murray. Ethanol increases superoxide production stimulated with phorbol myristate acetate in human polymorphonuclear leukocytes: Involvement of protein kinase C. Eur J Biochem 267:720-7, 2000. Evans AL and JJ Murray. Pharmacist, patient, and physician partnership in asthma management. Annals Allergy. Submitted. Keane BB, RE Esch and JJ Murray. Evaluation of DermaPIK as a skin testing device. J Allergy Clin Immunol. Submitted. Redfern D, BB Keane, RE Esch and JJ Murray. Comparison of grass extracts of various allergy units for epicutaneous testing. J Allergy Clin Immunol. Submitted.  Cross KSH, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Hypercholesterolemia-induced changes in vein graft vasomotor function. Ann Surg, submitted.  Truett AP III and JJ Murray. Activation of Phospholipase D in human polymorphonuclear leukocytes. FEBS Lett, submitted. Mullins MD, WE Serafin and JJ Murray. Characterization of immune cell responses in man with ex vivo whole blood assays: effects of the stable prostaglandin E analog misoprostol. J Immunol Meth, submitted.  Murray JJ. Is there a yeast connection for sinusitis? Sinus Newsletter. 2000. Vitola JV, JP Holsinger, DA Ingram, JB Atkinson, MB Forman, and JJ Murray. Mechanism of Fluosol in Ameliorating Myocardial Reperfusion Injury due to Prolonged Effects on Neutrophils by its Detergent Component and not due to Enhanced O2 Delivery. Am Heart J, submitted. Ingram DA, JP Holsinger, JB Atkinson, MB Forman and JJ Murray. Activation of neutrophils and complement by RheothRX: Mechanism of action in reducing myocardial reperfusion injury. J Cardiovascular Pharmacol, submitted. Banovac F, AP Truett III, JC Gay and JJ Murray. Effects of incubation conditions on human neutrophil responses. J Immunol Methods, submitted.  Hagaman D, JV Vitola and JJ Murray. Thrombocytopenia induced by multiple antibiotics. J Allergy Clin Immunol, submitted. Murray JJ. Editorial. Taking Control of Asthma: Current clinical guidelines in the treatment of asthma. In Presentations in Focus - Reports and Expert Commentary.Medical Education Network, New York, 1998.  Banovac F, AP Truett III, JC Gay and JJ Murray. Effects of calyculin on superoxide generation and phospholipase D activation of human neutrophils: effects of incubation conditions. J Leuk Biol, in preparation. Murray JJ. Asthma: Contemporary issues in pathogenesis and treatment. Annenberg Center Teleconference Educational Network. Pp. 4-10, 1998.  Murray JJ, Alexander J, BB Keane, LE Metcalf, M Moran, G O'Bryan-Tear, and HR Knapp. Effects in man of SC-45662, a 5-lipoxygenase inhibitor, after acute nasal allergen challenge, in preparation. Foreman MB, JV Vitola, CE Velasco, JJ Murray, RK Dubrey and EK Jackson. Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J Pharmacol Exp Ther 292:929-38, 2000.  Vitola JV, E Norton, EK Jackson, MB Forman and JJ Murray. Reduction of infarct size by adenosine A1 receptor activation. In preparation. Baraniuk J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards L, Srebro S and K Rickard. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 116:625-32, 1999. Dworski R, JJ Murray, LJ Roberts, JA Oates, JD Morrow, L Fisher and JR Sheller. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med 160:1947-51, 1999. Fish JE, E Israel, JJ Murray, A Emmet, R Boone, SW Yancey, and KA Rickard. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients on concomitant inhaled corticosteroid therapy. Chest, Submitted. Hartert TV, JJ Murray, JR Sheller, and JA Oates. Prostaglandin E2 decreases allergen stimulated release of prostaglandin D2 in airways of subjects with asthma, Am J Respir Crit Care Med, accepted. Converse GM, JD Duncavage, SB Tanner, JJ Murray, and J Bracikowski. Outcome analysis of recurrent acute and chronic sinus management: A proposed classification and treatment protocol with results. Submitted. Stein CM, AJ Sadeque, JJ Murray, C Wandel, RB Kim, GR Wilkinson, and AJJ Wood. Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans and Caucasians, submitted. Radassi K and JJ Murray. Effects of short exposure to a 60 Hz magnetic field on calcium uptake and microbicial functions in human neutrophils. Bioelectromagnetics, accepted with revisions. Murray JJ. Stepped care management of asthma. Trans American Academy Otolaryngology, 2000, submitted.  Kemp JP, GE Stewart, ME Ruff, JJ Murray and JE Harrison. Mometasone Furoate administered once-daily is as effective as twice-daily for treatment of patients with mild to moderate persistent asthma, submitted. Murray JJ, I Solomon, D McCluskey, J Zhang, R Palmer and G Notario. Efficacy of clarithromycin extended-release in the treatment of adult patients with acute maxillary sinusitis. Clin Therap, submitted. Murray JJ, R Nathan, E Bronsky, AO Olufade, D Chapman and B Kramer. Cetirizine in the management of seasonal allergic rhinitis: Impact on patient health-related work productivity and work impairment. Submitted. Abstracts Murray JJ, PW Reed and FS Fay. Effects of the divalent cation ionophore A23187 on isolated smooth muscle cells. Fed Proc 34:361, 1975.  Murray JJ, PW Reed and JG Dobson. Role of the divalent cation ionophore A23187 and isoproterenol on contractility, cyclic nucleotides and phosphorylase in cardiac muscle. Fed Proc 35:535, 1976.  Murray JJ, JG Dobson and PW Reed. Role of calcium in the effects of A23187 on cardiac muscle. Fed Proc 35:1707, 1976.  Ochillo RF, JJ Murray, BVR Sastry and EJ Landon. Influence of temperature and cold storage on the Ca2+ pump activities of the muscularis muscle of Bufo marinus. Fed Proc 37:558, 1978. Murray JJ, J Nowak, JA Oates and GA FitzGerald. Biosynthesis of thromboxane A2 and prostacyclin during cigarette smoking and withdrawal in man. Clin Res 33:521A, 1985. Murray JJ, AR Brash, LJ Roberts II, JA Workman, AB Tonnel, P Gosset, A Capron and JA Oates. Prostaglandin D2 is released during acute allergic bronchospasm in man. Clin Res 33:594A, 1985.  Murray JJ and AR Brash. Rabbit reticulocyte lipoxygenase selectively oxygenates arachidonic acid esterified in phosphatidylcholine. Clin Res 33:350A, 1985. Murray JJ, J Nowak, JA Oates and GA FitzGerald. Platelet function during chronic smoking and withdrawal. Clin Res 33:350A, 1985.  Sheller JR, JE Loyd, SS Duke, JJ Murray, AW Gillette, AW Malcolm, BO Meyrick and KL Brigham. Effect of thoracic irradiation on airway responsiveness in sheep. Am Rev Respir Dis 131:A287, 1985. Nowak J, JJ Murray, JA Oates, GA FitzGerald. Platelet function and the in vivo formation of thromboxane A2 and prostacyclin during chronic smoking in man. Thrombos Haemos 54:174, 1985. Murray J and R Snyderman. Evidence for subcellular redistribution of 5-lipoxygenase during human neutrophil activation by phlogistic stimuli. Clin Res 34:706A, 1986.  Hawkins DJ, BJ Meyrick and JJ Murray. Endothelium-derived relaxing factor may inhibit rabbit platelet aggregation. Clin Res 34:306A, 1986.  GA FitzGerald, JJ Murray, J Nowak and JA Oates. Effect of smoking on the endogenous production of prostacyclin and thromboxane and the in vivo platelet function in man. Smoking and Health: A national status report. 397, 1986.  Thompson KA, JJ Murray, IA Blair, RL Woosley and DM Roden. Plasma concentration of quinidine, its major active metabolites and dihydroquinidine in patients with Torsades de Pointes. Clin Res 34:408A, 1986.  Dillon SB, JJ Murray and R Snyderman. Regulation of inositol phosphate metabolism in human polymorphonuclear leukocytes (PMNs): Definition of two metabolic pathways for 1,4,5-IP3 production. Fed Proc 46:2287, 1987. Cox JB, R Snyderman and JJ Murray. Inhibition of 5-lipoxygenase translocation and activation in human neutrophils by microtubular disruption. Clin Res 35:472A, 1987.  Cross KSH, MN El-Sanadiki, JJ Murray, RL McCann and P-O Hagen. The role of prostaglandins in the altered vasoreactivity of vein grafts to norepinephrine and histamine. Circulation 76 (suppl 4): IV-482, 1987.  Murray JJ, I Fridovich, DJ Hawkins and P-O Hagen. Stabilization of the labile smooth muscle and platelet activity of EDRF. J Endocrinol 115(suppl):9, 1987.  Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Mast cell influx into autogenous vein grafts may contribute to vasospasm. Arteriosclerosis 7:528a, 1987.  Dillon SB, JJ Murray and R Snyderman. Production of inositol triphosphate isomers in human neutrophils. In: Advances in second messenger and phosphoprotein research. Eds: R Adelstein, C Klee and M Rodbell. Raven Press, New York. 21A:236, 1988.  Cox JB and JJ Murray. Mechanism of 5-lipoxygenase activation in cells from bronchoalveolar lavage (BAL) in normals and pulmonary fibrosis patients. Am Rev Resp Dis 137(4):356, 1988. Truett AP III, R Snyderman and JJ Murray. Increased diacylglycerol in stimulated human polymorphonuclear leukocytes appears unrelated to phosphatidylcholine hydrolysis: novel assay for phosphorylcholine. Clin Res 37:473A, 1988. Chu A, JJ Murray, C-C Lin, M Russell, P-O Hagen and FR Cobb. Plasma cyclic GMP levels is a specific indicator for the physiologic effects of atrial natriuretic peptide. Clin Res 37:268A, 1988. Chu A, FR Cobb, P-O Hagen and JJ Murray. Effects of a partially purified endothelium-derived relaxing factor on coronary and peripheral vasculature in awake dogs. Clin Res 37:267A, 1988. El-Sanadiki EN, KSH Cross, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Normal endothelial function and decreased reactivity of experimental arterial grafts. Soc Vascular Surgery, June 14, 1988. Stephan CC, N Singh, JJ Murray and BV Rama Sastry. Estimation of nicotine and cotinine in plasma samples of tobacco smokers by high performance liquid chromatography. HPLC 88: 12:TU-P261. Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Mast cell infiltration: Possible functional significance in vein graft vasospasm. Forty-nine Annual Meeting of the Society of University Surgeons 49:20, 1988. Schuman RW, KSH Cross, MN El-Sanadiki, ZS Radic, JJ Murray and P-O Hagen. Reduction of vein graft intimal hyperplasia by a free radical scavenger. Circulation 78:II-452, 1988 El-Sanadiki MN, KSH Cross, JJ Murray, RL McCann and P-O Hagen. Chronic verapamil treatment causes enhanced reactivity of vein bypass grafts. Circulation 78:II-636, 1988. Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Abnormal endothelial cell function in vein grafts. The Thirteenth Sir Peter Freyer Surgical Symposium, Ireland, November, 1988.  Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Cellular mechanisms of vein graft failure. Lister Professorship and Lecture, Edinburgh, Scotland, October, 1988. Badr KF, MD Breyer, K Takahashi, JJ Murray, M Schwartzberg, J Ebert, T Inagami and R Harris. Mesangial cell, glomerular, and renal vascular responses to endothelin in the rat. Kidney 35:308, 1989. Tanner SB, EL Scott, SR Marney, Jr. and JJ Murray. Effects of antihistamines on urinary histamine and methylhistamine levels in vivo. Annals Allergy 62:261,1989.  Cox JB, CE Buckley, R Whorton and JJ Murray. Electrochemical detection of sulfite in human plasma. J Allergy Clin Immunol 83:183, 1989. Truett AP III, R Snyderman and JJ Murray. Evidence for phosphatidylcholine (PC)-specific phospholipase D activation in stimulated human polymorphonuclear leukocytes (PMNs). J Allergy Clin Immunol 83:311, 1989. Tanner SB, JL Morgan, EL Scott, SR Marney, Jr. and JJ Murray. Alteration of histamine metabolism in vivo by antihistamines. J Allergy Clin Immunol 83:301, 1989.  Murray JJ. Evidence for the translocation of the 5-lipoxygenase by functional and immunocytochemical assays during activation of human polymorphonuclear leukocytes. Winter Prostaglandin Meetings. Prostaglandins 37:518, 1989.  Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann and P-O Hagen. Increased intimal thickening and supersensitivity in vein grafts of hypercholesterolemic rabbits. International College Angiology, 31st Annual Meeting, in press. Badr KF, MD Breyer, JJ Murray, T Inagami, K Takahashi and RC Harris. Signal transduction mechanisms and functional responses to endothelin in rat kidney and cultured glomerular mesangial cells. J Vasc Med Biol 1:77, 1989. Cross KS, MN El-Sanadiki, JJ Murray, EM Mikat, RL McCann, and P-O Hagen. Abnormal vasomotor function of failed human coronary artery vein grafts. Surgical Research Society of Great Britain and Ireland, in press. Smith WB, SR Marney, and JJ Murray. Cockroach sensitivity in Middle Tennessee. Annals Allergy 64:98, 1990.Wyche D, SR Marney and JJ Murray. Mexican Tea reactivity in Tennessee. Annals Allergy 64:98, 1990. Gay JC, AB Fogo, RL Hoover, LL Swift, CR Decker, I Ichikawa and JJ Murray. Modulation of rat neutrophil function by dietary w3 fatty acid. Clin Res 38:11A, 1990. Fogo AB, JJ Murray, R Hoover, I Ichikawa and J Gay. "Bloodless" rat, a model to study the pathophysiologic role of specific circulating cell types in renal injuries. Clin Res 38:21A, 1990. Murray JJ. Endothelium-derived relaxing factor. Biophys J 57:12a, 1990. Murray JJ, JL Morgan and AP Truett III. Identification of phosphatidylcholine specific phospholipase D (PC-PLD) activity in particulate fractions of human leukocytes (PMNs). J Allergy Clin Immunol 85:179, 1990. Gay JC, AB Fogo, RL Hoover, LL Swift, CR Decker and JJ Murray. Modulation of rat neutrophil function by dietary omega 3 fatty acid. Clin Res 38:358A, 1990.  Murray JJ, AP Truett III, TT Dinh and DA Kennerly. Extraction and radioenzymatic quantitation of cellular choline and phosphorylcholine with low picomole sensitivity. Fed Proc 4:A2060,1990. Truett AP III, SB Bocckino, JL Morgan, LE King and JJ Murray. Brown recluse spider venom: A potential mechanism of toxicity. South Med J 83:25-18, 1990. Gay JC, AP Truett III and JJ Murray. Products of the phospholipase D Pathway mediate activation and priming of the respiratory burst in human neutrophils. Blood 76:180a, 1990. Wyche DL, SR Marney, Jr and JJ Murray. Why do patients stop their shots? Annals Allergy 66:71, 1991. Smith WB, RE Esch, SR Marney, Jr and JJ Murray. In vivo reactivity to cockroach species. Annals Allergy 66:99, 1991. Forman MB, R Vermani and JJ Murray. Perfluorochemicals and myocardial reperfusion injury, J Clin Hemorheology, 1991. Yamano Y, K Sasaki, N Iwai, S Bardhan, S Chaki, F Konishi, JJ Murray, M Hasegawa, Y Matsuda and T Inagami. Cloning of angiotensin II receptor from bovine adrenal cortex and rat kidney. Hypertension 18:410, 1991. Wyche DL, SR Marney, Jr and JJ Murray. Why do patients stop their shots? Immunology Allergy Practice 247:33, 1991. Morrow JA, JJ Murray and MB Forman. Activated neutrophils may significantly contribute to increased adenosine levels reperfused myocardium. Circulation 84:II-84, 1991. Ingram DA, JJ Murray and MB Forman. Complement activation by Fluosol® may contribute to its beneficial effect in myocardial reperfusion injury. J Amer Coll Cardiol 19:373A, 1992. Ingram DA, MB Forman and JJ Murray. Fluosol® activates human neutrophils via phagocytosis: A novel therapeutic approach to reduce myocardial reperfusion injury. J Amer Coll Cardiol 19:58A, 1992. Morrow JA, MB Forman and JJ Murray. Enhanced endothelin production during myocardial ischemia stimulates adenosine release from neutrophils: A possible protective mechanism against reperfusion injury. J Amer Coll Cardiol 19:131A, 1992.  Truett AP III and JJ Murray. Tumor necrosis factorα potentiates the phospholipase D signalling pathway in human neutrophils. Clin Res, 39:817A, 1991.  Alexander J, B Keane, LE Metcalf, M Moran, G O'Bryan-Tear, HR Knapp and JJ Murray. Effects in man of SC-45662, a 5-lipoxygenase inhibitor, after acute nasal allergen challenge. J Allergy Clin Immunol 89:208, 1992. Truett AP III and JJ Murray. Tumor necrosis factorα potentiates the phospholipase D signalling pathway in human neutrophils. J Allergy Clin Immunol 89:308, 1992. Gay JC, AP Truett III and JJ Murray. Phosphatase activity regulates superoxide anion (O2-) generation and phospholipase D activity in human neutrophils. Clin Res 40:342A, 1992. Redfern DC, BB Keane, RE Esch and JJ Murray. Optimal concentration of standardized grass extracts for epicutaneous testing. Ann Allergy, 70:92 1993. DuBuske L, JJ Murray, J Klimas and J Condemi. REACT: A dose-ranging evaluation of the safety and efficacy of cetirizine in allergic rhinitis. Ann Allergy 70:92, 1993.  Vitola JV, TW Rigsby, DA Ingram, JB Atkinson, JJ Murray and MB Forman. The beneficial effect of Fluosol® to reduce myocardial reperfusion injury is independent of its oxygen carrying ability. J Am Coll Cardiol 21:399A, 1993. Forman MB, CE Velasco, TW Rigsby, J Vitola, EK Jackson and JJ Murray. Modulation of neutrophil function in vivo utilizing adenosine receptor antagonist: A novel therapy for myocardial reperfusion injury. J Am Coll Cardiol 21:85A, 1993. Serafin WE, W Burch, H Quershi and JJ Murray. Endothelin activates mast cells and is a substrate for mast cell carboxypeptidase A. J Allergy Clin Immunol 91:255, 1993. Vitola JV, JA Morrow, DA Ingram, JJ Murray and MB Forman. Lidocaine Reduces Infarct Size in the Rabbit Model of Myocardial Reperfusion Injury and Inhibits Neutrophil Activation in Vitro. Circulation, 88:I-545, 1993. Vitola JV, JP Holsinger, JB Atkinson, EK Jackson, MB Forman, and JJ Murray. Endothelin Antagonists Prevent Hemodynamic Changes, Arrhythmias and Death with Infused Endothelin but do not Alter Myocardial Salvage in a Reperfusion Injury Model. Circulation 90:I 35, 1994.  Kane G, M Pollice, J Cohn, J Murray, J Fish, and S Peters. Controlled trial of the effect of a 5-LO inhibitor on lung inflammation produced by segmental antigen challenge. J Allergy Clin Immunol 93:184, 1994.  Mullins MD, WE Serafin, and JJ Murray. Immunomodulatory effects of the stable prostaglandin E analog misoprostol in vivo. J Allergy Clin Immunology 93:203, 1994. Kane G, M Pollice, J Cohn, R Dworski, JJ Murray, JR Sheller, C-J Kim, J Fish, and S Peters. Insights into mechanisms of IgE mediated human lung inflammation derived from segmented antigen challenge studies employing a 5-lipoxygenase inhibitor. Am J Resp Crit Care Med, 149:A946, 1994. Dworski R, JJ Murray, and JR Sheller. Effect of acute administration of a 5-lipoxygenase inhibitor (Zileuton) on airway eicosanoids in asthma. Am J Resp Crit Care Med, 149:A946, 1994. Tolino M, G Kane, J Cohn, R Dworski, J Sheller, J Murray, J Fish, and SP Peters. Sulfidopeptide leukotrienes in IGEmediated early and late airway reactions in humans. Am J Resp Crit Care Med, 149:A531, 1994. Kane G, M Pollice, M Tolino, J Cohn, R Dworski, J Murray, J Sheller, C-J Kim,J Fish, and S Peters. The effect of Zileuton on eosinophil influx and leukotriene release in humans undergoing segmental antigen challenge. Int All Clin Immunol, in press. Vitola JV, DA Ingram, JP Holsinger, JB Atkinson, MB Forman, and JJ Murray. Fluosol Reduces Myocardial Reperfusion Injury by Prolonged Suppression of Neutrophils by its Detergent Component (RheothRx) and not by Enhancing O2 Delivery. J Amer Coll Cardiol, 25:103A, 1995. Vitola JV, JP Holsinger, JB Atkinson, MB Forman and JJ Murray. Inhibition of Neutrophil Function By Lidocaine as a Mechanism for the Beneficial Effect to Reduce Myocardial Reperfusion Injury. J Amer Coll Cardiol, 25:102A, 1995. Juniper EF, L Dube, L Swanson and the Zileuton study group (JJ Murray et al). The effect of Zileuton, a 5-lipoxygenase inhibitor, on asthma quality of life. Asthma '95. Chicago, 1995. ALA/ATS Abstracts. Israel E, J Cohn, L Dube and the Zileuton study group (JJ Murray et al). Chronic 5-lipoxygenase inhibition by zileuton significantly decreases the requirement for acute steroid treatment of asthma. Asthma '95. Chicago, 1995. ALA/ATS Abstracts. Hagaman D, JV Vitola and JJ Murray. Thrombocytopenia induced by multiple antibiotics. Annals Allergy, in press. Vitola JV, JP Holsinger, MB Forman, EK Jackson, M Kawana, T Quertermous and JJ Murray. Endothelin ETA/B Receptor Antagonist Reduces Infarct Size: A Novel Therapy for Acute Myocardial Infarction. J Am Coll Card, 25:310A, 1995. Vitola JV, E Norton, JJ Murray, EK Jackson and MB Forman. Adenosine Reduces Myocardial Reperfusion Injury Through A1 Receptor Activation in the Absence of Lidocaine. Circulation, submitted.  Vitola JV, MK Winters, JL Morgan, DA Ingram, MB Forman and JJ Murray. Blunting of the Effects of Fluosol and RheothRx by Lidocaine and Propranolol: A Possible Explanation for Disparate Clinical Effects. Circulation, submitted.  Vitola JV, M Kawana, J Holsinger, EK Jackson, T Quertermous, MB Forman and JJ Murray. Endothelin Messenger RNA Increases Following Reperfusion of Ischemic Myocardium. Circulation 92 I: 455-456, 1995.  Murray JJ, DD Hagaman, R Dworski and JR Sheller. Effect of Salmeterol and Belomethasone on the Late Phase Response to Segmental Antigen Challenge in Man. International Respiratory Forum, London England 1995. Keeler S and JJ Murray. Effects of prostaglandins on aspirin sensitive asthma. Southeast Allergy Meeting, 1996. Evans AL and JJ Murray. Pharmacist, patient, and physician partnership in asthma management. Am Soc Hosp Pharm, in press 1995. Eades JR and JJ Murray. Prevalence of Latex Sensitivity Among Health Care Workers in an Allergy Clinic. J Allergy Clin Immunol 97:324, 1996. Sandidge DR, JJ Murray and RB Leftwich. Correlation of asthma exacerbations and environmental factors in Middle Tennessee: The importance of mold. J Allergy Clin Immunol 97:378, 1996. LaForce C, F Hampel, F Kiechel, W Lumbry, JJ Murray, G Feiss, JA Furst, B Simpson and JA Smith. Comparison of once-daily triamcinolone acetonide aqueous nasal spray and twice- daily Beconase AQ for the treatment of seasonal allergic rhinitis due to ragweed. J Allergy Clin Immunol 97:433, 1996. In KH, K Asano, W Busse, E Israel, A Fischer, J Kemp, D Ledford, JJ Murray, A Segal, D Tinkleman and JM Drazen. Polymorphisms in the human 5-lipoxygenase gene sequence identified in normal and asthmatic subjects. Am J Resp Crit Care Med 155, 1996. Eades JR, SR Marney, Jr, A Hawkins, and JJ Murray. Intravenous vs. oral methylprednisolone in the treatment of asthma. Annals Allergy, in press,1996. Lazarus SC, TM Lee, S Wright, P Sarocco, L Rosentein, S Bjaleck-Smith, L Dube and the Zileuton Safety Group including JJ Murray. Secondary outcomes analysis of zileuton plus usual care vs usual care alone in the treatment of patients with asthma. Annals Allergy, in press, 1996. Eades JR, BB Keane, HW Cullom and JJ Murray. Prevalence and Temporal Relationship of Food Sensitivity in Latex Allergic Patients. J Allergy Clin Immunol 99:S503, 1997. Sahn S, S Galant, J Murray, E Bronsky, S Spector, I Faiferman, P Stober. Pranlukast (Ultair) improves FEV1 in patients with asthma: Results of a 12-week multi center study vs nedocromil. Am J Resp Crit Care Med 156, 1997. Weinstein SF, JJ Murray, E Kerwin, NL Church, AH Emmett, ME Wisiewski, WH Anderson, KA Rickard. The effect of adding Serevent to Beclovent versus doubling the dose of Beclovent on pulmonary function in symptomatic asthmatic patients ³18 years of age. Am J Resp Crit Care Med, in press, 1997. Burress R and JJ Murray. Effect of intranasal Astelin on skin test reactivity. Southeast Allergy Assoc, 1997. Murray J, B Bowers, F Cox, A Emmett, C Kalberg, V Petrocella, K Rickard. Salmeterol (42μg BID) improves adolescent and adults with moderate to severe asthma. J Allergy Clin Immunol 99:S325, 1997. Murray JJ, B Friedman, P Chervinsky, C Fogarty, JW Baker, PR Roagnes, L Edwards, WR Lincourt W, K Rickard. Asthma severity as a determinant for selecting appropriate doses of fluticasone propionate or beclomethasone dipropionate. J Allergy Clin Immunol 101:S232, 1998. Raphael GD, JW Baker, P Chervininsky, J Grossman, MF Goldstein, PR Roganes, WR Lincort and the FP study Group including JJ Murray. Low dose fluticasone proprionate is more effective than higher doses of beclomethasone diproprionate in patients with mild to moderate asthma. J Allergy Clin Immunol 101:S232, 1998. Murray JJ, Hagaman DD, Dworski R and JR Sheller. Effects of salmeterol on late phase asthmatic response. Am J Resp Crit Care Med, 157: A872, 1998. Bergeron K, Marney SR, and JJ Murray. Association of urticaria with chronic sinusitis. J Allergy Clin Immunol, 101:S154, 1998. Rickard KA, SG Kelsen, BQ Lanier, JJ Murray, AH Emmett, WH Anderson, NL Church. A six month comparison of adding salmeterol to doubling the dose of beclomethasone in asthma patients with symptoms on inhaled steroids. J Allergy Clin Immunol 101:S232, 1998. Murray JJ, B Friedman, P Chervinsky, C Fogarty, JW Baker, PR Roganes, L Edwards, and WR Lincourt. Flucticasone propionate (FP) is more effective than higher doses of beclomethasone diproprionate in patients with moderate asthma. Am J Resp Crit Care Med 157: A407, 1998. Hartert TV, RT Dworski, JA Oates, JJ Murray and JR Sheller. Prostaglandin E2 decreases allergen stimulated release of prostaglandin D2 in patients with asthma. Am J Resp Crit Care Med 157: A717, 1998. Vitola JV, E Norton , EK Jackson, MB Forman and JJ Murray. Infarct size reduction by activation of the adenosine A1 receptor during myocardial reperfusion. Am J. Cardiol 31:962(Suppl C), 1998. Radassi K and JJ Murray. Effects of 60 Hz magnetic field exposure on human neutrophil activation. Ann Review Research Biological Effects Elect Magnetic Fields P-15, 45, 1998. Karim A and JJ Murray. Bioavailibilty of misoprostol. Clin Pharm Therap, 1998.  Murray JJ, R Nathan, E Bronsky, AO Olufade, D Chapman and B Kramer. Cetirizine in the management of seasonal allergic rhinitis: Impact on patient health-related work productivity and work impairment. Annals Allergy, 1999. Dworski R, L Fisher, JJ Murray, LJ Roberts, JA Oates, JD Morrow, and JR Sheller. Allergen-induced increase in urinary and bronchoalveolar lavage (BAL) F-isoprostanes, 8-epi-PGF2a in atopic asthmatics. Am J Respir Crit Care Med 159:A96, 1999. Stein CM, JJ Murray and AJJ Wood. A rapid pharmacodynamic measure to determine interindividual variability in response to cyclosporine. Clin Pharm Therap, 65:160, 1999. Duncavage JA, SB Tanner, JJ Murray, and J Bracikowski. Prospective analysis of sinus symptoms and correlation with CT scan. Otolaryngology - Head and Neck Surgery, 1999. Duncavage JA, SB Tanner, JJ Murray, and J Bracikowski. Outcome analysis of recurrent acute and chronic sinusitis management. Otolaryngology - Head and Neck Surgery, 1999. Bracikowski JP, SB Tanner, JA Duncavage and JJ Murray. Asthma, Sinus, Allergy Program: ASAP centers - an improvement model. J Allergy Clin Immunol, S70, 1999. Stein CM, AJ Sadeque, JJ Murray, C Wandel, RB Kim, GR Wilkinson, and AJJ Wood. Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans and Caucasians, Clin Pharm Therap, 65:160, 1999. Murray JJ. Long term safety of mometasone furonate administered by dry powder inhaler in patients with moderate persistent asthma. Eur Respir Soc, 2000. Overholt J and JJ Murray. Inhaled lysine aspirin challenge and COX-2 inhibitors in aspirin sensitive asthmatics. Southeastern Allergy Society, 2000. Murray JJ, R Nathan, E Bronsky, AO Olufade, D Chapman and B Kramer. Cetirizine in the management of seasonal allergic rhinitis: Impact on patient health-related work productivity and work impairment. Transpacific Allergy Soc, 2000. Kemp JP, GE Stewart, MD Ruff, JJ Murray, and JE Harrison. Both once-daily and twice daily mometasone furoate provide additional improvement in patients previously maintained on short-acting inhaled beta2-agonists. J Allergy Clin Immunol 105: S10, 2000.  Benoit CM, JA Duncavage, SB Tanner, and JJ Murray. Comparison of nasal nitric oxide levels with findings on CT scan of the paranasal sinuses in patie4nts with symptoms of sinusitis. Am Acad Otolaryngology, submitted. Dworski R, JJ Murray, LJ Roberts, JA Oates, JD Morrow, L Fisher and JR Sheller. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane,15-F2-IsoP(8-iso-PGF2). Am J Respir Crit Care Med 161:A331, 2000. Murray JJ, I Solomon, D McCluskey, J Zhang, R Palmer and G Notario. Efficacy of clarithromycin extended-release in the treatment of adult patients with acute maxillary sinusitis. Clin Therap, submitted. Return to top A service of © 1996-2008 all rights reserved